Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2000

View Archived Issues

Prous Science presents: Case Histories of Drug Discovery

Company Profile: Siga

PAX9 gene mutation results in missing teeth

Delayed treatment with AM-36 reduces neuronal damage in stroke model

CV Therapeutics establishes Tangier drug discovery program

Addition of infliximab to methotrexate therapy reduces RA symptoms

Compounds and methods for treating or preventing HIV infection and AIDS

Japanese investigators prepare new agents for influenza

Novel Pfizer compounds useful for hyperproliferative disorders

Inhibitors of calmodulin-dependent PDE discovered at Daiichi

AstraZeneca presents new series of insulin sensitizers

Peptides binding to GRP receptors useful for diagnosis, treatment of certain tumors

Novel cis-cyclopropanes from BMS act as melatonin agonists

Cambridge NeuroScience and Algos enter pain management agreement

Maxamine granted orphan drug status for AML

Condensed heterocycles and ester prodrugs as potent antiplatelet, antithrombotic agents

Medarex enters cataract and cancer partnership with Scil Biomedicals

RWJ-67657 undergoes further study based on favorable preliminary biological profile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...